| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
|
N Engl J Med
|
2008
|
28.42
|
|
2
|
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
|
N Engl J Med
|
2015
|
18.66
|
|
3
|
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.
|
Lancet
|
2004
|
12.92
|
|
4
|
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.
|
Lancet
|
2010
|
12.21
|
|
5
|
Fibrinolysis for patients with intermediate-risk pulmonary embolism.
|
N Engl J Med
|
2014
|
9.33
|
|
6
|
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
|
N Engl J Med
|
2013
|
6.01
|
|
7
|
Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials.
|
Stroke
|
2008
|
3.21
|
|
8
|
The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke.
|
Stroke
|
2006
|
2.43
|
|
9
|
Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).
|
Stroke
|
2008
|
2.24
|
|
10
|
Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale.
|
Stroke
|
2009
|
1.72
|
|
11
|
Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials.
|
Stroke
|
2007
|
1.62
|
|
12
|
Thrombolysis during resuscitation for out-of-hospital cardiac arrest.
|
N Engl J Med
|
2008
|
1.54
|
|
13
|
Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA).
|
Stroke
|
2010
|
1.53
|
|
14
|
Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis.
|
Stroke
|
2009
|
1.44
|
|
15
|
Thrombolysis in stroke despite contraindications or warnings?
|
Stroke
|
2013
|
1.40
|
|
16
|
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
|
Diab Vasc Dis Res
|
2013
|
1.36
|
|
17
|
Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials.
|
Stroke
|
2006
|
1.31
|
|
18
|
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
|
Cardiovasc Diabetol
|
2014
|
1.12
|
|
19
|
A statistical model for the dependence between progression-free survival and overall survival.
|
Stat Med
|
2009
|
1.08
|
|
20
|
On the variability of covariate adjustment. experience with Koch's method for evaluating the absolute difference in proportions in randomized clinical trials.
|
Control Clin Trials
|
2002
|
1.01
|
|
21
|
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
|
Am Heart J
|
2010
|
0.99
|
|
22
|
Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).
|
Int J Stroke
|
2012
|
0.88
|
|
23
|
Can multivariable risk-benefit profiling be used to select treatment-favorable patients for thrombolysis in stroke in the 3- to 6-hour time window?
|
Stroke
|
2006
|
0.88
|
|
24
|
A new nonparametric approach for baseline covariate adjustment for two-group comparative studies.
|
Biometrics
|
2008
|
0.87
|
|
25
|
Selection for delayed intravenous alteplase treatment based on a prognostic score.
|
Int J Stroke
|
2013
|
0.75
|
|
26
|
How is retrospective independent review influenced by investigator-introduced informative censoring: a quantitative approach.
|
Stat Med
|
2011
|
0.75
|
|
27
|
Exploration of time-course combinations of outcome scales for use in a global test of stroke recovery.
|
Int J Stroke
|
2013
|
0.75
|